Business
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical collaboration to conduct a Phase 1 trial in China, planned to begin in 2026.
About this update from Carsgen Therapeutics Holdings Ltd.
[{"type":"text","content":"SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical collaboration to conduct a Phase 1 trial in China, planned to begin in 2026.","length":437,"tagName":"p"},{"type":"image","alt":"CARsgen and Dispatch Bio Announce Clinical Collaboration","displaySize":"","headline":null,"caption":"CARsgen and Dispatch Bio Announce Clinical Collaboration","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":136,"url":"https://media.zenfs.com/en/prnewswire.com/e36752b9213c5bfa4aea09b2bf26cd0a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Whitnzixk33v.bzQJkf_PA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI0MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e36752b9213c5bfa4aea09b2bf26cd0a","width":400,"height":136}},"href":"https://mma.prnewswire.com/media/2858985/CARsgen_Dispatch_Bio_Announce_Clinical_Collaboration.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The trial will evaluate DISP-11, an investigational therapy leveraging Dispatch's first-in-class Flare platform – including DV-10, the company's novel tumor-specific virus – and CARsgen's zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), an autologous B-cell maturation antigen (BCMA)-targeting CAR T-cell therapy, in patients suffering from solid tumors. Zevor-cel is approved by the National Medical Products Administration (NMPA) in China for the treatment of multiple myeloma.","length":502,"tagName":"p"},{"type":"text","content":""CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies," said Zonghai Li, M.D., Ph.D., Founder, Chairman of the Board, Chief Executive Officer and Chief Scientific Officer of CARsgen. "Dispatch's Flare platform offers a differentiated and highly complementary approach to expanding where and how CAR T can be applied, particularly for solid tumors lacking specific targets. We are excited to explore this combination as part of our broader efforts to unlock meaningful benefit for patients."","leng...